Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device Start-Ups Reap More Corporate Venture

This article was originally published in Start Up

Executive Summary

Corporate VCs are increasingly becoming a stable supplier of capital to medical device companies. Corporate investors have been participating in a growing percentage of deals being done, according to Elsevier’s Strategic Transactions, and remain focused on later-stage rounds.

You may also be interested in...



Late-Stage Venture Continues To Dominate Medtech Financing

Device start-ups raised $1.7 billion in 2013, and approximately 75% of the total was from Series C or later rounds, a sign that investors are still more comfortable making investments in more advanced companies.

Financings Of The Fortnight Checks The Corporate Venture Numbers

Corporate venture investment is seen as increasingly important in life sciences finance. Plus news on recent financings by Retrophin, Sophiris Bio, Regado Biosciences and Tigercat Pharma.

Medtech Start-Up Financing Strategies: Where’s The Money?

Despite the dire headlines, VCs are still investing in medtech start-ups, although the deals are becoming fewer and later stage. Start-ups looking for funding have to be more creative and look beyond traditional sources of funding, according to a discussion by six European venture capitalists speaking at the IN3 meeting in Dublin in April 2013.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel